This Article Full Text (PDF) All Versions of this Article: 0891988708327810v1 22/1/3    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fellgiebel, A. Articles by Fahrenholz, F. Search for Related Content PubMed PubMed Citation Articles by Fellgiebel, A. Articles by Fahrenholz, F. Pubmed/NCBI databases Medline Plus Health Information Alzheimer's Disease Social Bookmarking                         What's this?

CSF APPs and Phosphorylated Tau Protein Levels in Mild Cognitive Impairment and Dementia of Alzheimer's Type

Department of Psychiatry, Johannes Gutenberg University Mainz, Germany, fellgiebel{at}psychiatrie.klinik.uni-mainz.de

Elzbieta Kojro, PhD

Institute of Biochemistry, Johannes Gutenberg University Mainz, Germany

Matthias J. Muller, MD, PhD

Department of Psychiatry, Johannes Gutenberg University Mainz, Germany

Armin Scheurich, PhD

Department of Psychiatry, Johannes Gutenberg University Mainz, Germany

Lutz G. Schmidt, MD, PhD

Department of Psychiatry, Johannes Gutenberg University Mainz, Germany

Falk Fahrenholz, PhD, Dr.hc

Institute of Biochemistry, Johannes Gutenberg University Mainz, Germany

We exploratively measured APPs, a secreted fragment of the non-amyloidogenic cleavage of amyloid precursor protein via a-secretase, and tau protein phosphorylated at threonine 181 (ptau) in the cerebrospinal fluid of 10 patients with mild cognitive impairment, 20 patients with dementia of Alzheimer's type, and 10 controls. Cerebrospinal fluid APPs and ptau levels were correlated with cognitive performance. Ptau levels were significantly elevated in mild cognitive impairment and in patients with dementia of Alzheimer's type, APPs levels were significantly reduced in patients with dementia of Alzheimer's type compared to the controls. APPs levels were associated with Mini Mental State Examination total scores but not with Delayed Verbal Recall Test performance. Vice versa, ptau levels correlated only with Delayed Verbal Recall Test in patients with dementia of Alzheimer's type or mild cognitive impairment. Both, an increase in ptau levels and a decrease in cerebrospinal fluid APPs, seem to refer to relevant but functionally different processes in the development of mild cognitive impairment and dementia of Alzheimer's type.

Key Words: APPs • phosphorylated tau proteins • MCI • Alzheimer disease • biomarker

This version was published on March 1, 2009

Journal of Geriatric Psychiatry and Neurology, Vol. 22, No. 1, 3-9 (2009)
DOI: 10.1177/0891988708327810


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?